Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD.

Laboratory of Adipose Tissue Biology Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-2682.

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64.

Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145-171.

Spooner MH, Jump DB. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Curr Opin Clin Nutr Metab Care. 2019;22(2):103-110.

Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation. Hepatology. 2020;71(4):1213-1227.

Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-689.

Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-923.

Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2019;1(4):312-328.

Younossi ZM, Tampi RP, Racila A, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care. 2020;43(2):283-289.

European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.

Ruissen MM, Mak AL, Beuers U, Tushuizen ME, Holleboom AG. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur J Endocrinol. 2020;183(3):R57-R73.

Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-484.

Roche HM, Gibney MJ. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr. 2000;71(1 Suppl):232S-237S.

Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Mol Aspects Med. 2018;64:135-146.

Musa-Veloso K, Venditti C, Lee HY, et al. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutr Rev. 2018;76(8):581-602.

Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108-125.

Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62(1):190-197.

Caldwell S. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017;23(2):103-108.

Lu FS, Nielsen NS, Timm-Heinrich M, Jacobsen C. Oxidative stability of marine phospholipids in the liposomal form and their applications. Lipids. 2011;46(1):3-23.

Rossmeisl M, Medrikova D, van Schothorst EM, et al. Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. Biochim Biophys Acta. 2014;1841(2):267-278.

Paluchova V, Vik A, Cajka T, et al. Triacylglycerol-rich oils of marine origin are optimal nutrients for induction of polyunsaturated docosahexaenoic acid ester of hydroxy linoleic acid (13-DHAHLA) with anti-inflammatory properties in mice. Mol Nutr Food Res. 2020;64(11):e1901238.

Burri L, Hoem N, Banni S, Berge K. Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci. 2012;13(11):15401-15419.

Rossmeisl M, Jilkova ZM, Kuda O, et al. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PLoS One. 2012;7(6):e38834.

Rossmeisl M, Pavlisova J, Bardova K, et al. Increased plasma levels of palmitoleic acid may contribute to beneficial effects of Krill oil on glucose homeostasis in dietary obese mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(8):158732.

Burri L, Johnsen L. Krill products: an overview of animal studies. Nutrients. 2015;7(5):3300-3321.

Liu X, Xue Y, Liu C, et al. Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis. 2013;12:109.

Ding L, Wang D, Zhou M, et al. Comparative study of EPA-enriched phosphatidylcholine and EPA-enriched phosphatidylserine on lipid metabolism in mice. J Oleo Sci. 2016;65(7):593-602.

Liu Y, Shi D, Tian Y, et al. Eicosapentaenoic acid-enriched phosphatidylcholine attenuated hepatic steatosis through regulation of cholesterol metabolism in rats with nonalcoholic fatty liver disease. Lipids. 2017;52(2):119-127.

Zhang LY, Ding L, Shi HH, et al. Eicosapentaenoic acid in the form of phospholipids exerts superior anti-atherosclerosis effects to its triglyceride form in ApoE(-/-) mice. Food Funct. 2019;10(7):4177-4188.

Zhang L, Ding L, Shi H, et al. Eicosapentaenoic acid-enriched phospholipids suppressed lipid accumulation by specific inhibition of lipid droplet-associated protein FSP27 in mice. J Sci Food Agric. 2020;100(5):2244-2251.

Tang X, Li ZJ, Xu J, et al. Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet. Lipids Health Dis. 2012;11:70.

Hosomi R, Fukunaga K, Nagao T, et al. Effect of dietary oil rich in docosahexaenoic acid-bound lysophosphatidylcholine prepared from fishery by-products on lipid and fatty acid composition in rat liver and brain. J Oleo Sci. 2019;68(8):781-792.

Chang M, Zhang T, Han X, et al. Comparative analysis of EPA/DHA-PL forage and liposomes in orotic acid-induced nonalcoholic fatty liver rats and their related mechanisms. J Agric Food Chem. 2018;66(6):1408-1418.

Hosomi R, Fukunaga K, Nagao T, et al. Effect of dietary partial hydrolysate of phospholipids, rich in docosahexaenoic acid-bound lysophospholipids, on lipid and fatty acid composition in rat serum and liver. J Food Sci. 2019;84(1):183-191.

Chen L, Takatani N, Beppu F, Miyashita K, Hosokawa M. The effect of n-3 PUFA binding phosphatidylglycerol on metabolic syndrome-related parameters and n-3 PUFA accretion in diabetic/obese KK-A(y) mice. Nutrients. 2019;11(12).2866

Bjørndal B, Vik R, Brattelid T, et al. Krill powder increases liver lipid catabolism and reduces glucose mobilization in tumor necrosis factor-alpha transgenic mice fed a high-fat diet. Metabolism. 2012;61(10):1461-1472.

Piscitelli F, Carta G, Bisogno T, et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond). 2011;8(1):51.

Ferramosca A, Conte A, Burri L, et al. A krill oil supplemented diet suppresses hepatic steatosis in high-fat fed rats. PLoS One. 2012;7(6):e38797.

Ferramosca A, Conte L, Zara V. A krill oil supplemented diet reduces the activities of the mitochondrial tricarboxylate carrier and of the cytosolic lipogenic enzymes in rats. J Anim Physiol Anim Nutr (Berl). 2012;96(2):295-306.

Yang G, Lee J, Lee S, et al. Krill oil supplementation improves dyslipidemia and lowers body weight in mice fed a high-fat diet through activation of amp-activated protein kinase. J Med Food. 2016;19(12):1120-1129.

Parolini C, Bjorndal B, Busnelli M, et al. Effect of dietary components from antarctic krill on atherosclerosis in apoE-deficient mice. Mol Nutr Food Res. 2017;61(12):1700098.

Kroupova P, van Schothorst EM, Keijer J, et al. Omega-3 phospholipids from krill oil enhance intestinal fatty acid oxidation more effectively than omega-3 triacylglycerols in high-fat diet-fed obese mice. Nutrients. 2020;12(7):2037.

Sistilli G, Kalendova V, Cajka T, et al. Krill oil supplementation reduces exacerbated hepatic steatosis induced by thermoneutral housing in mice with diet-induced obesity. Nutrients. 2021;13(2):437.

Burri L, Berge K, Wibrand K, Berge RK, Barger JL. Differential effects of krill oil and fish oil on the hepatic transcriptome in mice. Front Genet. 2011;2:45.

Sadzuka Y, Sugiyama I, Miyashita M, et al. Beneficial effects by intake of Euphausiacea pacifica on high-fat diet-induced obesity. Biol Pharm Bull. 2012;35(4):568-572.

Tillander V, Bjørndal B, Burri L, et al. Fish oil and krill oil supplementations differentially regulate lipid catabolic and synthetic pathways in mice. Nutr Metab (Lond). 2014;11:20.

Helal MG, El-Kashef DH. Krill oil alleviates oxidative stress, iron accumulation and fibrosis in the liver and spleen of iron-overload rats. Environ Sci Pollut Res Int. 2020;27(4):3950-3961.

Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev. 2004;9(4):420-428.

Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res. 2014;34(2):126-133.

Berge RK, Ramsvik MS, Bohov P, et al. Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study. Lipids Health Dis. 2015;14:163.

Cicero AF, Rosticci M, Morbini M, et al. Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. Arch Med Sci. 2016;12(3):507-512.

Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. 2009;29(9):609-615.

Banni S, Carta G, Murru E, et al. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond). 2011;8(1):7.

Berge K, Piscitelli F, Hoem N, et al. Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis. 2013;12:78.

Sarkkinen ES, Savolainen MJ, Taurio J, Marvola T, Bruheim I. Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure. Lipids Health Dis. 2018;17(1):287.

Rundblad A, Holven KB, Bruheim I, Myhrstad MC, Ulven SM. Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial. J Nutr Sci. 2018;7:e3.

Rundblad A, Holven KB, Bruheim I, Myhrstad MC, Ulven SM. Effects of fish and krill oil on gene expression in peripheral blood mononuclear cells and circulating markers of inflammation: a randomised controlled trial. J Nutr Sci. 2018;7:e10.

Lobraico JM, DiLello LC, Butler AD, Cordisco ME, Petrini JR, Ahmadi R. Effects of krill oil on endothelial function and other cardiovascular risk factors in participants with type 2 diabetes, a randomized controlled trial. BMJ Open Diabetes Res Care. 2015;3(1):e000107.

Albert BB, Derraik JG, Brennan CM, et al. Supplementation with a blend of krill and salmon oil is associated with increased metabolic risk in overweight men. Am J Clin Nutr. 2015;102(1):49-57.

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351.

Kammoun HL, Chabanon H, Hainault I, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest. 2009;119(5):1201-1215.

Tandy S, Chung RW, Wat E, et al. Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice. J Agric Food Chem. 2009;57(19):9339-9345.

Sanders FW, Griffin JL. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016;91(2):452-468.

Walker AK, Jacobs RL, Watts JL, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell. 2011;147(4):840-852.

Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr. 2016;7(1):5-13.

Dentin R, Benhamed F, Pegorier JP, et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest. 2005;115(10):2843-2854.

Jelenik T, Rossmeisl M, Kuda O, et al. AMP-activated protein kinase alpha2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes. 2010;59(11):2737-2746.

Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295.

Batetta B, Griinari M, Carta G, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr. 2009;139(8):1495-1501.

Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci. 2017;38(7):649-665.

Sanderson LM, de Groot PJ, Hooiveld GJ, et al. Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PLoS One. 2008;3(2):e1681.

Vigerust NF, Bjorndal B, Bohov P, Brattelid T, Svardal A, Berge RK. Krill oil versus fish oil in modulation of inflammation and lipid metabolism in mice transgenic for TNF-alpha. Eur J Nutr. 2013;52(4):1315-1325.

Liu X, Cui J, Li Z, et al. Comparative study of DHA-enriched phospholipids and EPA-enriched phospholipids on metabolic disorders in diet-induced-obese C57BL/6J mice. Eur J Lipid Sci Technol. 2014;116(3):255-265.

Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Gottlicher M, Rustan AC. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J. 1999;343(Pt 1):191-197.

Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;89(1):1-8.

Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. Vasc Health Risk Manag. 2015;11:511-524.

Scherer PE. The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2019;62(2):223-232.

Flachs P, Mohamed-Ali V, Horakova O, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 2006;49(2):394-397.

Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475-490.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology. 2011;53(1):346-355.

Svegliati-Baroni G, Patricio B, Lioci G, Macedo MP, Gastaldelli A. Gut-pancreas-liver axis as a target for treatment of NAFLD/NASH. Int J Mol Sci. 2020;21(16):5820.

Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42.

Durkin LA, Childs CE, Calder PC. Omega-3 polyunsaturated fatty acids and the intestinal epithelium-A review. Foods. 2021;10(1):199.

Grimstad T, Bjorndal B, Cacabelos D, et al. Dietary supplementation of krill oil attenuates inflammation and oxidative stress in experimental ulcerative colitis in rats. Scand J Gastroenterol. 2012;47(1):49-58.

Costanzo M, Cesi V, Palone F, et al. Krill oil, vitamin D and Lactobacillus reuteri cooperate to reduce gut inflammation. Benef Microbes. 2018;9(3):389-399.

Kim JH, Hong SS, Lee M, et al. Krill Oil-Incorporated Liposomes As An Effective Nanovehicle To Ameliorate The Inflammatory Responses Of DSS-Induced Colitis. Int J Nanomedicine. 2019;14:8305-8320.

Liu F, Smith AD, Solano-Aguilar G, et al. Mechanistic insights into the attenuation of intestinal inflammation and modulation of the gut microbiome by krill oil using in vitro and in vivo models. Microbiome. 2020;8(1):83.

Prossomariti A, Scaioli E, Piazzi G, et al. Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Sci Rep. 2017;7(1):7458.

Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 2018;67(11):1974-1983.

Ye J, Lv L, Wu W, et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels. Front Microbiol. 2018;9:1967.

Xu Z, Tang H, Huang F, et al. Algal oil rich in n-3 PUFA alleviates DSS-induced colitis via regulation of gut microbiota and restoration of intestinal barrier. Front Microbiol. 2020;11:615404.

Hu S, Du M, Su L, Yang H. Phosphatidylserine from portunus trituberculatus eggs alleviates insulin resistance and alters the gut microbiota in high-fat-diet-fed mice. Mar Drugs. 2020;18(9):483.

Lu C, Sun T, Li Y, Zhang D, Zhou J, Su X. Modulation of the gut microbiota by krill oil in mice fed a high-sugar high-fat diet. Front Microbiol. 2017;8:905.

Morishita M, Tanaka T, Shida T, Takayama K. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release. 2008;132(2):99-104.

Pavlisova J, Horakova O, Kalendova V, et al. Chronic n-3 fatty acid intake enhances insulin response to oral glucose and elevates GLP-1 in high-fat diet-fed obese mice. Food Funct. 2020;11(11):9764-9775.

Tou JC, Jaczynski J, Chen YC. Krill for human consumption: nutritional value and potential health benefits. Nutr Rev. 2007;65(2):63-77.

de Souza CO, Teixeira AAS, Biondo LA, Lima Junior EA, Batatinha HAP, Rosa Neto JC. Palmitoleic acid improves metabolic functions in fatty liver by PPARalpha-dependent AMPK activation. J Cell Physiol. 2017;232(8):2168-2177.

Sharma L, Lone NA, Knott RM, Hassan A, Abdullah T. Trigonelline prevents high cholesterol and high fat diet induced hepatic lipid accumulation and lipo-toxicity in C57BL/6J mice, via restoration of hepatic autophagy. Food Chem Toxicol. 2018;121:283-296.

Zhang J, Yang A, Wu Y, et al. Stachydrine ameliorates carbon tetrachloride-induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats. Biomed Pharmacother. 2018;97:1586-1594.

Ursoniu S, Sahebkar A, Serban MC, et al. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2017;75(5):361-373.

Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD